Idiopathic HES may need long-term IL-5 inhibition (e.g., mepolizumab) to maintain remission, in contrast to imatinib-sensitive HES, where targeted therapy prevents relapse (17). This evidence concerns the gene IL5 and hypereosinophilic syndrome.